Myosin Therapeutics to Pitch MT-125 at BioFuture 2026 in New York
Jupiter, Florida – October 16, 2026 -- Myosin Therapeutics will present its first-in-class cancer candidate MT-125 at BioFuture 2026 in New York City on October 27–28, seeking investors and pharmaceutical partners to fund an extension into two additional treatment-resistant cancers.
CEO Courtney Miller joins oncology panel on October 27
Chief Executive Officer Courtney Miller, PhD, will speak on the panel "Beyond the Cure: The Brave New World of Revolutionary Cancer Therapeutics." The session covers next-generation cell therapies, AI-enabled cancer drug discovery, precision medicines and advanced therapeutic platforms. Participating CEOs will introduce their companies, followed by a moderated round-robin discussion.
Chief Medical Officer Karen Smith, MD, PhD, MBA, LLM, will join Miller for investor and strategic partner meetings throughout the conference.